Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme

Vincenzo Sforza; Erika Martinelli; Claudia Cardone; Giulia Martini; Stefania Napolitano; Pietro Paolo Vitiello; Pasquale Vitale; Nicoletta Zanaletti; Alfonso Reginelli; Maurizio Di Bisceglie; Tiziana Pia Latiano; Anna Maria Bochicchio; Fabiana Cecere; Francesco Selvaggi; Fortunato Ciardiello; Teresa Troiani

doi:10.1136/esmoopen-2017-000229

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme

Vincenzo Sforza, Erika Martinelli, Claudia Cardone, Giulia Martini, Stefania Napolitano, Pietro Paolo Vitiello, Pasquale Vitale, Nicoletta Zanaletti, Alfonso Reginelli, Maurizio Di Bisceglie, Tiziana Pia Latiano, Anna Maria Bochicchio, Fabiana Cecere, Francesco Selvaggi, Fortunato Ciardiello, Teresa Troiani

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: TAS-102 improves overall survival (OS) in patients with metastatic colorectal cancer (mCRC) refractory to standard treatments. However, predictive biomarkers of efficacy are currently lacking. PATIENTS AND METHODS: We treated a cohort of 43 chemorefractory mCRC patients treated with TAS-102, in a single institution expanded access, compassionate use programme. We stratified patients in two groups according to number of cycles received (

Original language	English
Pages (from-to)	e000229
Journal	ESMO Open
Volume	2
Issue number	4
DOIs	https://doi.org/10.1136/esmoopen-2017-000229
Publication status	Published - 2017

Access to Document

10.1136/esmoopen-2017-000229

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623320/

Fingerprint Dive into the research topics of 'Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme'. Together they form a unique fingerprint.

Cite this

Sforza, V., Martinelli, E., Cardone, C., Martini, G., Napolitano, S., Vitiello, P. P., Vitale, P., Zanaletti, N., Reginelli, A., Bisceglie, M. D., Latiano, T. P., Bochicchio, A. M., Cecere, F., Selvaggi, F., Ciardiello, F., & Troiani, T. (2017). Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open, 2(4), e000229. https://doi.org/10.1136/esmoopen-2017-000229

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. / Sforza, Vincenzo; Martinelli, Erika; Cardone, Claudia; Martini, Giulia; Napolitano, Stefania; Vitiello, Pietro Paolo; Vitale, Pasquale; Zanaletti, Nicoletta; Reginelli, Alfonso; Bisceglie, Maurizio Di; Latiano, Tiziana Pia; Bochicchio, Anna Maria; Cecere, Fabiana; Selvaggi, Francesco; Ciardiello, Fortunato; Troiani, Teresa.

In: ESMO Open, Vol. 2, No. 4, 2017, p. e000229.

Research output: Contribution to journal › Article › peer-review

Sforza, V, Martinelli, E, Cardone, C, Martini, G, Napolitano, S, Vitiello, PP, Vitale, P, Zanaletti, N, Reginelli, A, Bisceglie, MD, Latiano, TP, Bochicchio, AM, Cecere, F, Selvaggi, F, Ciardiello, F & Troiani, T 2017, 'Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme', ESMO Open, vol. 2, no. 4, pp. e000229. https://doi.org/10.1136/esmoopen-2017-000229

Sforza, Vincenzo ; Martinelli, Erika ; Cardone, Claudia ; Martini, Giulia ; Napolitano, Stefania ; Vitiello, Pietro Paolo ; Vitale, Pasquale ; Zanaletti, Nicoletta ; Reginelli, Alfonso ; Bisceglie, Maurizio Di ; Latiano, Tiziana Pia ; Bochicchio, Anna Maria ; Cecere, Fabiana ; Selvaggi, Francesco ; Ciardiello, Fortunato ; Troiani, Teresa. / Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. In: ESMO Open. 2017 ; Vol. 2, No. 4. pp. e000229.

@article{98866f29d4fc44a58f49e80b710aece9,

title = "Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme",

abstract = "BACKGROUND: TAS-102 improves overall survival (OS) in patients with metastatic colorectal cancer (mCRC) refractory to standard treatments. However, predictive biomarkers of efficacy are currently lacking. PATIENTS AND METHODS: We treated a cohort of 43 chemorefractory mCRC patients treated with TAS-102, in a single institution expanded access, compassionate use programme. We stratified patients in two groups according to number of cycles received (",

author = "Vincenzo Sforza and Erika Martinelli and Claudia Cardone and Giulia Martini and Stefania Napolitano and Vitiello, {Pietro Paolo} and Pasquale Vitale and Nicoletta Zanaletti and Alfonso Reginelli and Bisceglie, {Maurizio Di} and Latiano, {Tiziana Pia} and Bochicchio, {Anna Maria} and Fabiana Cecere and Francesco Selvaggi and Fortunato Ciardiello and Teresa Troiani",

year = "2017",

doi = "10.1136/esmoopen-2017-000229",

language = "English",

volume = "2",

pages = "e000229",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "BMJ Publishing Group",

number = "4",

}

TY - JOUR

T1 - Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme

AU - Sforza, Vincenzo

AU - Martinelli, Erika

AU - Cardone, Claudia

AU - Martini, Giulia

AU - Napolitano, Stefania

AU - Vitiello, Pietro Paolo

AU - Vitale, Pasquale

AU - Zanaletti, Nicoletta

AU - Reginelli, Alfonso

AU - Bisceglie, Maurizio Di

AU - Latiano, Tiziana Pia

AU - Bochicchio, Anna Maria

AU - Cecere, Fabiana

AU - Selvaggi, Francesco

AU - Ciardiello, Fortunato

AU - Troiani, Teresa

PY - 2017

Y1 - 2017

N2 - BACKGROUND: TAS-102 improves overall survival (OS) in patients with metastatic colorectal cancer (mCRC) refractory to standard treatments. However, predictive biomarkers of efficacy are currently lacking. PATIENTS AND METHODS: We treated a cohort of 43 chemorefractory mCRC patients treated with TAS-102, in a single institution expanded access, compassionate use programme. We stratified patients in two groups according to number of cycles received (

AB - BACKGROUND: TAS-102 improves overall survival (OS) in patients with metastatic colorectal cancer (mCRC) refractory to standard treatments. However, predictive biomarkers of efficacy are currently lacking. PATIENTS AND METHODS: We treated a cohort of 43 chemorefractory mCRC patients treated with TAS-102, in a single institution expanded access, compassionate use programme. We stratified patients in two groups according to number of cycles received (

U2 - 10.1136/esmoopen-2017-000229

DO - 10.1136/esmoopen-2017-000229

M3 - Article

VL - 2

SP - e000229

JO - ESMO Open

JF - ESMO Open

SN - 2059-7029

IS - 4

ER -